PharmaTher logo

PharmaTher(OTC) PHRRF

Market Cap$3.69MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-77%
5 Year-92%
1 Year-58%
1 Month+15%
$0.04
-4.26%
-0.00Today
PharmaTher last closing stock price
MetricPriceDate
Last closeUSD 0.042026-10-16
PharmaTher stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.46%USD 0.042026-10-09
1 month+14.73%USD 0.042026-09-16
3 month+14.73%USD 0.042026-07-17
Year to date-42.14%USD 0.072025-12-31
1 year-58.38%USD 0.102025-10-16
3 year-64.65%USD 0.112023-10-17
5 year-92.21%USD 0.522021-10-15
Since inception-77.49%USD 0.182020-11-25

PharmaTher Financials at a Glance

Market Cap

$3.69MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$0.00

Net Income (TTM)

-CA$609.85K

EPS (TTM)

-$0.00

P/E Ratio

-8.27

Dividend

$0.00

Beta (Volatility)

0.33 (Low)

Price

$0.04

Volume

59,208

Open

$0.04

Previous Close

$0.04

Daily Range

$0.04 - $0.04

52-Week Range

$0.03 - $0.12

Estimated Earnings Date

Oct 28, 2026

PHRRF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About PharmaTher

PharmaTher Holdings Ltd. is a biotechnology firm focused on developing innovative psychedelic treatments for mental health issues, neurological diseases, and chronic pain. The company is advancing several products through clinical trials, aiming to address significant unmet medical needs.

Products and Services
  • Intravenous ketamine injection for Parkinson's disease and ALS
  • Ketamine Patch for depression and pain management
  • PHARMAPATCH for transdermal delivery of psychedelic compounds
Growth Outlook
  • Strong pipeline with multiple products in Phase II and III clinical trials
  • Strategic partnerships enhancing development capabilities and market reach
  • Increasing interest in psychedelic therapies driving market potential
Financial Highlights
  • Recent quarterly net income of -$2,364, reflecting ongoing R&D investments
  • Cash and short-term investments of $861,389, providing operational runway
  • Current ratio of 1.64, indicating solid liquidity position
PharmaTher Holdings Ltd. is positioned in a rapidly evolving sector, with a focus on psychedelic therapies that are gaining traction in the medical community. The company's diverse product pipeline, including the intravenous ketamine injection and the Ketamine Patch, showcases its commitment to addressing critical health challenges. With strategic partnerships in place, PharmaTher is well-equipped to navigate the complexities of drug development and commercialization. Recent financial data indicates a focus on research and development, with significant investments aimed at bringing innovative solutions to market. The company's liquidity position, supported by cash reserves, allows for continued operational activities as it advances its clinical trials. Overall, PharmaTher Holdings Ltd. represents a compelling opportunity in the biotechnology space, particularly for those interested in the potential of psychedelic treatments.
AI Generated • Sep 24, 2026

Industry

Pharmaceuticals

Sector

Health Care

CEO

Fabio Chianelli

Website

www.pharmather.com

Headquarters

Toronto, ON M5C 1P1, CA

PHRRF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-98.98%

Return on Capital

-139.56%

Return on Assets

-54.39%

Earnings Yield

-12.09%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.69MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

91.02M

Volume

59.21K

Avg. Volume

131.77K

Financials (TTM)

Gross Profit

CA$0.00

Operating Income

-CA$915.85K

EBITDA

-CA$856.20K

Operating Cash Flow

-CA$484.85K

Capital Expenditure

CA$3.00

Free Cash Flow

-CA$484.85K

Cash & ST Invst.

CA$922.13K

Total Debt

CA$0.00

PharmaTher Performance Analysis

PharmaTher annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-05-31CAD 0N/A
20242024-05-31CAD 0N/A
20252025-05-31CAD 0N/A
20262026-05-31CAD 0N/A
PharmaTher sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-08-31N/A
Q22025-11-30N/A
Q32026-02-28N/A
Q42026-05-31N/A
PharmaTher annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-05-31CAD -0.0539.0%
20242024-05-31CAD -0.03-52.1%
20252025-05-31CAD -0.01-52.5%
20262026-05-31CAD -0.00-60.5%
PharmaTher sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-08-3135.1%
Q22025-11-3043.7%
Q32026-02-28100.0%
Q42026-05-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

CA$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$3.69MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$737.26K

N/A

Employees

5

N/A

Net Income

CA$79.58K

+119.5%

EBITDA

CA$35.39K

+106.7%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

CA$922.13K

-17.9%

Total Debt

CA$0.00

N/A

Accounts Receivable

CA$7.90K

N/A

Inventory

CA$0.00

N/A

Long Term Debt

CA$0.00

N/A

Short Term Debt

CA$0.00

N/A

Return on Assets

-54.39%

N/A

Return on Invested Capital

-1.38%

N/A

Free Cash Flow

-CA$106.60K

+64.7%

Operating Cash Flow

-CA$106.60K

+64.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BIXTBioxytran, Inc.
$0.02-0.43%
LIANYLianMedical
$0.05+0.00%
CUBTCurative Biotechnology, Inc.
$0.91-4.27%
THERTheralink Technologies, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$89.85-5.79%
NVDANvidia
$214.13-1.43%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$93.67-12.74%
CCCCCC Intelligent Solutions
$7.61-0.26%

Questions About PHRRF

What is the current price of PharmaTher?

PharmaTher is trading at $0.04 per share.

What is the 52-week range for PharmaTher?

Over the past 52 weeks, PharmaTher has traded between $0.03 and $0.12.

How much debt does PharmaTher have?

As of the most recent reporting period, PharmaTher reported total debt of CA$0.00.

How much cash does PharmaTher have on hand?

PharmaTher reported CA$499.59K in cash and cash equivalents in its most recent financial results.

What is PharmaTher’s dividend yield?

PharmaTher does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services